Daniel Zelterman

Yale University, New Haven, CT 
Biostatistics Biology
"Daniel Zelterman"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Crump K, Crouch E, Zelterman D, et al. (2020) Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate. Toxicological Sciences. 175: 156-167
Abu-Khalaf M, Pierobon M, Denduluri N, et al. (2019) Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3) Cancer Research. 79
Han G, Schell MJ, Zhang H, et al. (2016) Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. Biometrics
Stahl M, Podoltsev NA, DeVeaux M, et al. (2016) The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort Blood. 128: 1063-1063
Acevedo-Gadea C, Hatzis C, Chung G, et al. (2015) Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Research and Treatment. 150: 157-67
Ratner ES, Keane FK, Lindner R, et al. (2012) A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31: 4559-66
Saif MW, Hashmi S, Zelterman D, et al. (2008) Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review International Journal of Colorectal Disease. 23: 139-145
See more...